- Home
- JFU vs ACRV Comparison
JFU vs ACRV Comparison
Compare JFU & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFU
- ACRV
- Stock Information
- Founded
- JFU 2006
- ACRV 2018
- Country
- JFU China
- ACRV United States
- Employees
- JFU N/A
- ACRV N/A
- Industry
- JFU Finance: Consumer Services
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- JFU Finance
- ACRV Health Care
- Exchange
- JFU Nasdaq
- ACRV Nasdaq
- Market Cap
- JFU 58.2M
- ACRV 47.8M
- IPO Year
- JFU 2019
- ACRV 2022
- Fundamental
- Price
- JFU $4.55
- ACRV $2.41
- Analyst Decision
- JFU
- ACRV Buy
- Analyst Count
- JFU 0
- ACRV 5
- Target Price
- JFU N/A
- ACRV $14.67
- AVG Volume (30 Days)
- JFU 7.5K
- ACRV 1.2M
- Earning Date
- JFU 12-09-2022
- ACRV 11-13-2025
- Dividend Yield
- JFU N/A
- ACRV N/A
- EPS Growth
- JFU 3110.57
- ACRV N/A
- EPS
- JFU 3.04
- ACRV N/A
- Revenue
- JFU $44,573,690.00
- ACRV N/A
- Revenue This Year
- JFU N/A
- ACRV N/A
- Revenue Next Year
- JFU N/A
- ACRV $805.34
- P/E Ratio
- JFU $1.48
- ACRV N/A
- Revenue Growth
- JFU 8.19
- ACRV N/A
- 52 Week Low
- JFU $1.01
- ACRV $1.05
- 52 Week High
- JFU $5.88
- ACRV $8.00
- Technical
- Relative Strength Index (RSI)
- JFU 50.98
- ACRV 62.55
- Support Level
- JFU $4.45
- ACRV $2.00
- Resistance Level
- JFU $4.82
- ACRV $2.35
- Average True Range (ATR)
- JFU 0.26
- ACRV 0.20
- MACD
- JFU -0.12
- ACRV 0.03
- Stochastic Oscillator
- JFU 17.46
- ACRV 89.28
About JFU 9F Inc.
9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company's operations are organized into Material segments, consisting of E-commerce services, technology Empowerment service and Wealth Management services, of which it derives maximum revenue from technology Empowerment service. All its revenues are generated from the People's Republic of China.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.